Last mentioned: Mar 6, 2026
Earnings Calls
Management teams for both companies host conference calls to provide strategic updates and 2026 outlook.
Transcript Release
Full transcripts of the Q4 2025 earnings calls are made available to the public and analysts.
SEC Filings
Both ACFN and CRMD file 8-K reports detailing Q4 and full-year 2025 financial results.
Acorn Energy and CorMedix both reported Q4 2025 financial results on March 5, 2026, marking a critical transition from development to commercial scaling. While Acorn focuses on high-margin IoT recurring revenue, CorMedix is navigating the complex rollout of its lead product, DefenCath, in the dialysis market.
CorMedix Inc. (NASDAQ: CRMD) reported its Q4 2025 financial results, highlighting the successful commercial ramp-up of DefenCath, the first FDA-approved antimicrobial catheter lock solution. The company is focusing on securing major dialysis organization contracts and optimizing reimbursement pathways to solidify its market position.
CorMedix and Acorn Energy reported strong Q4 2025 results, highlighting a year of significant commercial expansion for specialized healthcare and infrastructure solutions. CorMedix saw accelerated adoption of its antimicrobial catheter lock solution, DefenCath, while Acorn Energy’s OmniMetrix division capitalized on rising demand for remote monitoring in critical healthcare facilities.